Authors
Loading...
May advance oral GPIIb/IIIa antagonist development; leaves open clinical efficacy and safety.
Key points are not available for this paper at this time.
Eldred et al. (1994) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: